Moreover, a reduced survival rate at 28 days was shown in L412F COVID-19 patients treated with the autophagy-inhibitor hydroxychloroquine, suggesting that the outcome of clinical trials with hydroxychloroquine should be reinterpreted in the light of the TLR3-L412F polymorphism status [116]. Here, TLR3 is linked to COVID-19.